Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019.  The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies for prostate cancer. It is unclear to what extent do trial results apply to older patients, as they are significantly underrepresented in these trials.  In summary Dr. O'Sullivan stresses the need to consider age profiles when developing trial protocols, to make sure that elderly patients are appropriately represented in all clinical trials.

Biography:

Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of Radiation Oncology, Queen's University Belfast, Consultant Oncologist, Northern Ireland Cancer Center, Belfast

Related Content:

Written Coverage: APCCC 2019: The Aging Population: Onco-geriatric Assessment and Treatment Considerations

Download Presentation Slides